Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.7026
Abstract: 7026Background: Blocking PD-1/PD-L1 pathways enhances anti-leukemia responses in murine AML (Zhang et al, Blood 2009). PD-1 positive CD8 T-cells are increased in bone marrow (BM) of pts with AML (Daver et al, ASH 2016). AZA… read more here.
Keywords: phase; nivolumab azacytidine; aza; azacytidine aza ... See more keywords